reports
Medigene to Present at Upcoming Scientific Conferences
Medigene to Present at Upcoming Scientific Conferences (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, has been invited to present at the CHI's 8th Annual Immuno-Oncology Summit Europe from April 23-25, 2024, in London, UK, as well as at the 7th International Neoantigen Summit to be held in Amsterdam, Netherlands from April 29 - May 1, 2024. The presentations will be available on Medigene´s website after the conferences: Oral presentation: CHI's 8th Annual ...
Medigene Presents Favorable Safety Profile of TCR-T Cells with Costimu...
Medigene Presents Favorable Safety Profile of TCR-T Cells with Costimulatory Switch Protein at AACR Annual Meeting 2024 Planegg/Martinsried, April 8, 2024. (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, today presents superior recombinant T cell receptor (rTCR) engineered T cell functionality as well as a favorable safety profile when rTCR-T cells are armored and enhanced with the PD1-41BB costimulatory switch protein (CSP) at the American Association for Cance...
Medigene AG Secures European Patent for its iM-TCR Technology
Medigene AG Secures European Patent for its iM-TCR Technology Planegg/Martinsried, April 4, 2024. (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, today announced that the Company has been issued a patent by the European Patent Office protecting its inducible Medigene T cell receptor (iM-TCR) technology, which contains a control mechanism to regulate efficacy and improve safety of its T cell receptor engineered T cell (TCR-T) therapies. “Over the past years we have conscientio...
- Wedbush Research
MTB M&T BANK CORPORATION
VMW VMWARE INC. CLASS A
BLUE BLUEBIRD BIO INC.
ZION ZIONS BANCORPORATION N.A.
WTFC WINTRUST FINANCIAL CORPORATION
WDC WESTERN DIGITAL CORPORATION
WBS WEBSTER FINANCIAL CORPORATION
WAL WESTERN ALLIANCE BANCORP
VYGR VOYAGER THERAPEUTICS INC.
VLY VALLEY NATIONAL BANCORP
TCBI TEXAS CAPITAL BANCSHARES INC.
SRPT SAREPTA THERAPEUTICS INC.
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
SGMO SANGAMO THERAPEUTICS INC.
SBUX STARBUCKS CORPORATION
RGNX REGENXBIO INC.
RF REGIONS FINANCIAL CORPORATION
RARE ULTRAGENYX PHARMACEUTICAL INC.
PSTG PURE STORAGE INC. CLASS A
PPBI PACIFIC PREMIER BANCORP INC.
PB PROSPERITY BANCSHARES INC.(R)
PAYX PAYCHEX INC.
NYCB NEW YORK COMMUNITY BANCORP INC.
NVDA NVIDIA CORPORATION
NTAP NETAPP INC.
MU MICRON TECHNOLOGY INC.
MNKD MANNKIND CORP.
KEY KEYCORP
INTC INTEL CORPORATION
HMST HOMESTREET INC.
HBI HANESBRANDS INC.
HBAN HUNTINGTON BANCSHARES INCORPORATED
HAFC HANMI FINANCIAL CORPORATION
GOOGL ALPHABET INC. CLASS A
FITB FIFTH THIRD BANCORP
FHN FIRST HORIZON CORPORATION
FFWM FIRST FOUNDATION
EWBC EAST WEST BANCORP INC.
CVBF CVB FINANCIAL CORP.
CUBI CUSTOMERS BANCORP INC.
COLB COLUMBIA BANKING SYSTEM INC.
CFG CITIZENS FINANCIAL GROUP INC.
CATY CATHAY GENERAL BANCORP
BMRN BIOMARIN PHARMACEUTICAL INC.
BKU BANKUNITED INC.
BIIB BIOGEN INC.
BANC BANC OF CALIFORNIA INCORPORATED
AXTI AXT INC.
NFLX NETFLIX INC.
CFR CULLEN/FROST BANKERS INC.
2330 TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
BOKF BOK FINANCIAL CORPORATION
CMA COMERICA INCORPORATED
SLM SLM CORP
HPE HEWLETT PACKARD ENTERPRISE CO.
NTLA INTELLIA THERAPEUTICS INC.
HOPE HOPE BANCORP INC.
FCNCA FIRST CITIZENS BANCSHARES INC. CLASS A
ROKU ROKU INC. CLASS A
VRNA VERONA PHARMA ADS
AMZN AMAZON.COM INC.
AMD ADVANCED MICRO DEVICES INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
AVGO BROADCOM INC.
AX AXOS FINANCIAL INC.
DELL DELL TECHNOLOGIES INC CLASS C
LC LENDINGCLUB CORP
SMCI SUPER MICRO COMPUTER
PASG INC.
BEAM PASSAGE BIO
GBIO BEAM THERAPEUTICS
FUBO GENERATION BIO
BUR FUBOTV
FHTX BURFORD CAPITAL
MRVL FOGHORN THERAPEUTICS
STX MARVELL TECHNOLOGY INC
TSVT SEAGATE TECHNOLOGY HLDGS PLC
DSGN 2SEVENTY BIO INC
GFS DESIGN THERAPEUTICS INC
PEPG GLOBALFOUNDRIES INC
BROS PEPGEN INC
PRME DUTCH BROS INC
PRIME MEDICINE INC
- David Carlson
- David Nierengarten
- Dennis Pak
- Martin Fan
VYGR VOYAGER THERAPEUTICS INC.
SRPT SAREPTA THERAPEUTICS INC.
SGMO SANGAMO THERAPEUTICS INC.
RGNX REGENXBIO INC.
RARE ULTRAGENYX PHARMACEUTICAL INC.
MNKD MANNKIND CORP.
BMRN BIOMARIN PHARMACEUTICAL INC.
BIIB BIOGEN INC.
NTLA INTELLIA THERAPEUTICS INC.
VRNA VERONA PHARMA ADS
PASG PASSAGE BIO
BEAM BEAM THERAPEUTICS
GBIO GENERATION BIO
FHTX FOGHORN THERAPEUTICS
TSVT 2SEVENTY BIO INC
DSGN DESIGN THERAPEUTICS INC
PEPG PEPGEN INC
PRME PRIME MEDICINE INC
Medigene AG Reports Full-Year 2023 Financial Results and Provides Corp...
Medigene AG Reports Full-Year 2023 Financial Results and Provides Corporate Update Significant corporate and scientific progress in 2023Innovations to End-to-End Platform technologies and IP portfolioPipeline additions with multiple KRAS neoantigen targetsAdvancement of lead program MDG1015 with IND/CTA approval expected in 2H 2024 Partnering expansion with new scientific partnership with the National Cancer Institute and further collaboration for new costimulatory switch protein with Helmholtz MunichUpdates to strategy going forward to develop both TCR-T therapies and additional, non-autol...
- David Carlson
- David Nierengarten
- Dennis Pak
- Martin Fan
Medigene AG to participate in the H.C. Wainwright 2nd Annual Cell Ther...
Medigene AG to participate in the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference Planegg/Martinsried, March 19, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will be participating in the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference on March 26, 2024. Members of Medigene's management team will join a fireside chat and will be available for virtual one-on-one meetings with registered investors. --- end of press rele...
- Wedbush Research
ADS ADIDAS AG
BLUE BLUEBIRD BIO INC.
WDC WESTERN DIGITAL CORPORATION
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
QCOM QUALCOMM INC
PSTG PURE STORAGE INC. CLASS A
ORCL ORACLE CORPORATION
NVDA NVIDIA CORPORATION
NTAP NETAPP INC.
NCMI NATIONAL CINEMEDIA INC.
MU MICRON TECHNOLOGY INC.
LEN LENNAR CORPORATION CLASS A
INTC INTEL CORPORATION
GOOGL ALPHABET INC. CLASS A
FL FOOT LOCKER INC.
FB FACEBOOK INC. CLASS A
CNK CINEMARK HOLDINGS INC.
AXTI AXT INC.
AMC AMC ENTERTAINMENT HOLDINGS INC. CLASS A
SWKS SKYWORKS SOLUTIONS INC.
2330 TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
UAA UNDER ARMOUR INC. CLASS A
ALPN ALPINE IMMUNE SCIENCES
AMZN AMAZON.COM INC.
AMD ADVANCED MICRO DEVICES INC.
NKE NIKE INC. CLASS B
MSFT MICROSOFT CORPORATION
LEGH LEGACY HOUSING CORP
DDOG DATADOG INC CLASS A
SMCI SUPER MICRO COMPUTER
PHVS INC.
SNOW PHARVARIS NV
ONON SNOWFLAKE INC. CLASS A
STX ON HOLDING AG
GFS SEAGATE TECHNOLOGY HLDGS PLC
GLOBALFOUNDRIES INC
- David Carlson
- David Nierengarten
- Dennis Pak
- Martin Fan
Medigene AG to report full year 2023 financial results on March 28, 2...
Medigene AG to report full year 2023 financial results on March 28, 2024 Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will report financial results and provide a corporate update for the fiscal year ended December 31, 2023, on Thursday, March 28, 2024. Following the release of the full year 2023 earnings results and annual report on Medigene’s website, the Company will host a conference call that same day at 3 pm CET / 10 am ET. Full deta...
- Wedbush Research
MTB M&T BANK CORPORATION
BLUE BLUEBIRD BIO INC.
WSM WILLIAMS-SONOMA INC.
WBS WEBSTER FINANCIAL CORPORATION
VLY VALLEY NATIONAL BANCORP
NYCB NEW YORK COMMUNITY BANCORP INC.
FIS FIDELITY NATIONAL INFORMATION SERVICES INC.
ETSY ETSY INC.
CFG CITIZENS FINANCIAL GROUP INC.
BKU BANKUNITED INC.
BBY BEST BUY CO. INC.
AX AXOS FINANCIAL INC.
RH RESTORATION HARDWARE INC.
GBIO GENERATION BIO
ELEV ELEVATION ONCOLOGY
PEPG PEPGEN INC
- David Carlson
- David Nierengarten
- Dennis Pak
- Martin Fan
Medigene to Present Favorable Safety Profile of TCR-T Cells upon Addit...
Medigene to Present Favorable Safety Profile of TCR-T Cells upon Addition of Costimulatory Switch Protein with a Poster Presentation at AACR 2024 Annual Meeting Planegg/Martinsried, March 6, 2024. (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will present a poster at the American Association for Cancer Research Annual Meeting (AACR) 2024 taking place from April 5-10, 2024 in San Diego, USA as well as an oral presentation at the ELRIG-Forum 2024 to be held...
Medigene AG Expands Patent Portfolio in Japan for iM-TCR Technology to...
Medigene AG Expands Patent Portfolio in Japan for iM-TCR Technology to Directly Control TCR-T Safety and Efficacy, In Vivo Planegg/Martinsried, March 4, 2024. (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, today announced that the Company has been issued a patent by the Japan Patent Office protecting its inducible Medigene T cell receptor (iM-TCR), a control mechanism to regulate efficacy and safety of its T cell receptor engineered T cell (TCR-T) therapies. “We are delighte...
Medigene Presents at CAR-TCR Summit Europe Showcasing Unique Approach ...
Medigene Presents at CAR-TCR Summit Europe Showcasing Unique Approach for Development of Differentiated TCR-T Therapies Multiple members of management as expert speakers including Prof. Dr. Dolores Schendel, Chief Scientific Officer of Medigene, Dr. Barbara Lösch, Head of Technology & Innovation and Dr. Kirsty Crame, Vice President, Clinical Strategy & DevelopmentPresentations and seminars highlight key parts of Medigene’s proprietary End-to-End Platform by offering multiple solutions to address the challenges in TCR-T therapy development for treatment of solid tumors Planegg/Martinsrie...
Medigene to Present at Upcoming Conferences
Medigene to Present at Upcoming Conferences Planegg/Martinsried, February 19, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will present at the 7th CAR-TCR Summit Europe taking place February 27-29, 2024, in London as well as at the East-West Biopharma Summit to be held March 4-6, 2024, in Singapore. 7th CAR-TCR Summit Europe 2024 Presentation Date: February 28, 2024, 5:30 pm local timeLocation: London, UKPresenter: Prof...
Medigene Announces Indication Selection for the Clinical Development ...
Medigene Announces Indication Selection for the Clinical Development of its Lead 3rd Generation TCR-T Therapy Program in Solid Tumors Gastric cancer, ovarian cancer, myxoid/round cell liposarcoma and synovial sarcoma selected as initial clinical indications for lead program MDG1015MDG1015 is a first-in-class, third generation TCR-T therapy targeting NY-ESO-1/ LAGE-1a, armored and enhanced by costimulatory switch protein PD1-41BB Clinical development in both orphan and more common cancer indications addresses high unmet medical need in large patient populations Planegg/Martinsried, Febru...
- Wedbush Research
- David Carlson
- David Nierengarten
- Dennis Pak
- Martin Fan
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.